Selected article for: "antigen antibody and large scale"
Author: Ganneru, Brunda; Jogdand, Harsh; Daram, Vijaya Kumar; Das, Dipankar; Molugu, Narasimha Reddy; Prasad, Sai D.; Kannappa, Srinivas V.; Ella, Krishna M.; Ravikrishnan, Rajaram; Awasthi, Amit; Jose, Jomy; Rao, Panduranga; Kumar, Deepak; Ella, Raches; Abraham, Priya; Yadav, Pragya; Sapkal, Gajanan N.; Shete, Anita; Desphande, Gururaj Rao; Mohandas, Sreelekshmy; Basu, Atanu; Gupta, Nivedita; Vadrevu, Krishna Mohan
Title: Th1 Skewed immune response of Whole Virion Inactivated SARS CoV 2 Vaccine and its safety evaluation
  • Cord-id: w0oi9tcw
  • Document date: 2021_3_10
    • ID: w0oi9tcw
    Snippet: We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established Vero cell platform to produce large-scale GMP grade highly purified inactivated antigen. Product development and manufacturing process were carried out in a BSL-3 facility. Immunogenicity and safety was determined
    Document: We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established Vero cell platform to produce large-scale GMP grade highly purified inactivated antigen. Product development and manufacturing process were carried out in a BSL-3 facility. Immunogenicity and safety was determined at two antigen concentrations (3μg and 6μg), with two different adjuvants, in mice, rats and rabbits. Our results show that BBV152 vaccine formulations generated significantly high antigen-binding and neutralizing antibody titers (NAb), at both concentrations, in all three species with excellent safety profiles. The inactivated vaccine formulation containing TLR7/8 agonist adjuvant-induced Th1 biased antibody responses with elevated IgG2a/IgG1 ratio and increased levels of SARS-CoV-2 specific IFN-γ+ CD4+ T lymphocyte response. Our results support further development for Phase I/II clinical trials in humans.

    Search related documents:
    Co phrase search for related documents
    • absence presence and adjuvant absence presence: 1, 2
    • absence presence and adjuvant antigen: 1, 2, 3
    • absence presence and adjuvanted vaccine: 1
    • absence presence and long term immunity: 1, 2, 3, 4
    • absence presence and lymph node: 1, 2, 3, 4, 5
    • adaptive immune response and adjuvant activity: 1, 2, 3, 4
    • adaptive immune response and adjuvant antigen: 1, 2, 3, 4, 5
    • adaptive immune response and adjuvanted vaccine: 1
    • adaptive immune response and long term immunity: 1, 2
    • adaptive immune response and lymph node: 1, 2, 3, 4, 5, 6
    • adjuvant activity and lymph node: 1, 2, 3
    • adjuvant antigen and local reaction: 1
    • adjuvant antigen and lymph node: 1, 2, 3
    • adjuvanted vaccine and long term immunity: 1, 2
    • adjuvanted vaccine and lymph node: 1, 2, 3
    • long term immunity and lymph node: 1, 2, 3